J clin oncol 2005 23 6549-55

Author: nnse

August undefined, 2024

WebThis invention concerns methods of treating a patient diagnosed with glioblastoma comprising administering to said patient a therapy comprising an effective amount of an anti-VEGF antibody and a chemotherapeutic. WebFeb 20, 2024 · Favorable responses were achieved by 80%, with complete responses in 23 patients (77%) and a partial response with marker normalization in one patient. At a median follow-up of 33 months, 22 (73%) of the favorable …

Optimal therapy for patients with hepatocellular carcinoma and ...

WebJan 29, 2014 · J Clin Oncol. 2005. 23:6549-55. Ronnen EA, Kondagunta GV, Bacik J, et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin … WebMay 23, 2024 · J Clin Oncol. 2005;23: 6549-6555. Link, Google Scholar: 17. Nichols CR, Tricot G, Williams SD, et al. Dose-intensive chemotherapy in refractory germ cell cancer—a … bristol place group homes

Phase II multicenter study of the epidermal growth factor receptor

WebIntroduction. In China and all around the world, lung cancer remains the most common cause of death in cancer patients. 1 Of all lung cancers, non-small cell lung cancer (NSCLC), as a subclass, accounts for about 80–85% of the total incidence. 2 Adenocarcinoma is currently the predominant histological subtype of NSCLC. 3,4 The reported average 5-year … WebJ Clin Oncol. 2005;23(3):609–618. 14. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch repair deficiency. ... :52–55. 42. Patel JN. Cancer … WebApr 20, 2005 · 10.1200/JCO.2005.09.050 Abstract Purpose: This is the first study in which the NK(1)-receptor antagonist, aprepitant (APR), was evaluated for the prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy. Patients and methods: bristol pickers nh

Exercise interventions for advanced cancer palliative care …

J Clin Oncol. Request PDF - ResearchGate

WebJ Clin Oncol 23:6549-6555. © 2005 by American Society of Clinical Oncology INTRODUCTION Between 70% and 80% of patients with ad-vanced, metastatic germ cell … WebMay 28, 2024 · Introduction. The US Food and Drug Administration (FDA) approves cancer drugs based on (1) overall survival (OS) or patient reported outcomes, (2) progression-free survival, ie, the time until cancer recurs or worsens, or (3) response rate (RR), ie, the percent of patients experiencing tumor shrinkage. 1,2 Response rate and complete response rate … bristol place apartments baton rouge laWebAug 17, 2024 · J Clin Oncol. 2005 Dec 20. 23(36):9290-4. [QxMD MEDLINE Link] . Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J. Combination of paclitaxel, ifosfamide, and cisplatin is an... bristol picture framing

"WebAug 9, 2024 · 42. Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol (2005) 23(27):6549–55. doi: 10.1200/JCO.2005.19.638. PubMed Abstract CrossRef Full Text Google Scholar " - J clin oncol 2005 23 6549-55

J clin oncol 2005 23 6549-55

Chemotherapy for Extracranial Germ Cell Tumours in Paediatric ...

WebSep 20, 2005 · Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors J Clin Oncol. 2005 Sep … WebApr 27, 2024 · We systematically analyzed germ cell therapy trials with the goal of providing evidence for the efficacy of HDCT in the treatment of GCC. Our goal was to identify patient characteristics and...

Did you know?

WebIntroduction. Multiple myeloma is a hematological malignancy characterized by neoplastic proliferation of clonal plasma cells. 1 Several landmark advances have been made in the …

WebYou need to enable JavaScript to run this app. DocGuide. You need to enable JavaScript to run this app. WebJan 29, 2024 · J Clin Oncol. 2005. 23:6549-55. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J …

WebThe toxic effects of high-dose chemotherapy were primarily myelosuppression, mucositis, nausea, vomiting, dehydration, peripheral neuropathy, and otologic abnormalities. 8 There … WebOct 1, 2005 · J Clin Oncol 23: 6549-6555 Home Pharmacology Chemistry Pharmaceuticals Paclitaxel Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, Bosl GJ, Motzer RJCombination of...

WebJ Clin Oncol. 2005;23(19):4338–4346. 23. Villa E, Ferretti I, Grottola A, et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. ... Lancet Oncol. 2013;14(1):55–63. 38. The ASCO Post. FDA expands approved use of regorafenib for hepatocellular carcinoma. 2024 Apr 27 ...

WebJan 10, 2024 · Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy. … can you take food in your suitcase on a planeWebJul 27, 2009 · J Clin Oncol. 2005; 23 (abstr).: 624s Google Scholar Definitive estimates are now available for all endpoints; median follow-up for all patients was 22·5 months (range 0·9–125·1) and for those still alive at the final analysis was 69·3 months (6·2–125·1). bristol place aptsWebMar 5, 2014 · We did this phase 3 randomised controlled trial (EORTC 62012) at 38 hospitals in ten countries. We included patients with locally advanced, unresectable, or metastatic high-grade soft-tissue sarcoma, age 18–60 years with a WHO performance status of 0 or 1. can you take food in your suitcaseWebApr 8, 2024 · 55. Headley JA, Ownby KK, John Lauri D. The effect of seated exercise on fatigue and quality of life in women with advanced breast cancer. Oncol Nurs Forum 2004; 31(5): 977–983. Crossref. PubMed. ... J Clin Oncol 2005; 23(4): 899–909. Crossref. PubMed. ISI. Google Scholar. 59. bristol planning onlineWebApr 25, 2012 · XmAb2513 is a modified anti-CD30 antibody with increased binding affinity to the Fc receptor. In vitro data showed more potent and efficacious cell killing than first-generation anti-CD30 monoclonal antibodies XDA-060 and SGN-30. In clinical trials, only phase I data are available. bristol plate companyWebThe Journal of Clinical Oncology is a peer-reviewed medical journal published 3 times a month by the Lippincott Williams & Wilkins. It covers research on all aspects of clinical … bristol plate company gold plated spoonsWebMay 28, 2024 · J Clin Oncol (2005) 23:6549–55. doi: 10.1200/JCO.2005.19.638. PubMed Abstract CrossRef Full Text Google Scholar. 33. Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, et al. Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic … bristol players